Denali Therapeutics Inc. DNLI Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $418.78M+5.6% | $396.44M-6.5% | $423.88M+18.2% | $358.73M+35.2% | ||
| $136.56M+29.5% | $105.44M+2.0% | $103.35M+14.2% | $90.48M+14.4% | ||
| $555.34M+10.7% | $501.88M-4.8% | $527.23M+17.4% | $449.21M+30.4% | ||
| $555.34M+10.7% | $501.88M-4.8% | $527.23M+17.4% | $449.21M+30.4% | ||
| -$555.34M-14.0% | -$487.34M-148% | -$196.7M+42.3% | -$340.74M-15.2% | ||
| $42.9M-33.6% | $64.64M+25.5% | $51.51M+249% | $14.77M— | ||
| -$512.54M-21.2% | -$422.77M-191% | -$145.22M+55.5% | -$325.99M-12.2% | ||
| -$2.97-15.1% | -$2.58-137% | -$1.09+58.1% | -$2.60-8.8% | ||
| -$2.97-15.1% | -$2.58-146% | -$1.05+59.6% | -$2.60-8.8% | ||
| 687.7M+5.5% | 652.2M+18.0% | 552.5M+11.7% | 494.7M+1.9% | ||
| 687.7M+5.5% | 652.2M+18.9% | 548.6M+10.9% | 494.7M+1.9% | ||
| -$513.88M-21.9% | -$421.4M-206% | -$137.7M+58.3% | -$330.38M-12.8% | ||
| $42.9M-33.6% | $64.64M+25.5% | $51.51M+249% | $14.77M— | ||
| -$1.34M— | —— | $7.53M— | —— | ||
| -$555.34M-14.0% | -$487.34M-148% | -$196.7M+42.3% | -$340.74M-15.2% | ||
| -$544.16M-13.5% | -$479.55M-166% | -$179.97M+45.5% | -$330.36M-15.0% | ||
| -$544.16M-13.5% | -$479.55M-166% | -$179.97M+45.5% | -$330.36M-15.0% | ||
| -$555.34M-14.0% | -$487.34M-148% | -$196.7M+42.3% | -$340.74M-15.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Denali Therapeutics Inc.'s income statement data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.